Rheumatoid arthritis (RA) is the latest high-profile disease for which the Institute for Clinical and Economic Review (ICER) has constructed a “value framework” for assessing and comparing available drug treatments. In April, ICER issued a comprehensive, 529-page report on targeted immune modulators (TIMs) for RA that covers 14 medicines—all but two biologics, and none biosimilars. […]
Author: Marcus Dortch
HealthTrust Addressing Pharmacy Leadership Shortage With Unique Residency Program
In 2014, HealthTrust established the nation’s first corporate-based training program for future pharmacy leaders that provides early career exposure to critical business functions, value-based purchasing and the economic realities of modern medicine, including better management of limited healthcare resources.